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Aim. To determine serum IL-1β, IL-6, IL-8, and TNF-α levels in neonatal sepsis at the time of diagnosis and after therapy, and
to show the meaningful on the follow up. Methods. This prospective study was performed on newborns who were hospitalized
for neonatal sepsis and who were classiﬁed as culture-proven sepsis (n = 12), as culture-negative sepsis (n = 21), and as healthy
newborns (n = 17). Results. At the time of diagnosis, serum IL-1β,I L - 6 ,I L - 8 ,a n dT N F - α levels of culture-proven sepsis were
signiﬁcantly higher than those of the control groups (P<. 05). At the time of diagnosis, IL-1β,I L - 6 ,I L - 8 ,a n dT N F - α levels of
culture-proven sepsis and culture-negative sepsis were signiﬁcantly higher than levels at the seventh day after antibiotic treatment.
Conclusion.S e r u mI L - 1 β,I L - 6 ,I L - 8 ,a n dT N F - α are mediators of inﬂammation and can be used at the diagnosis and at the
evaluation of the therapeutic eﬃciency in neonatal sepsis.
Copyright © 2007 A. Nese Citak Kurt et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Bacterial infection in newborns, especially preterm, may
rapidly evolve into generalized sepsis. This condition has a
gradual and subtle onset, with nonspeciﬁc symptoms that
may severely compromise the infant’s clinical state if un-
treated and lead to life-threatening consequences. Neona-
tal sepsis has a fairly low incidence at birth (1–10/1000 live
births) but may aﬀect up to 16% of infants in the neona-
tal intensive care unit (NICU) with birth weight of 501–
1500gm. The mortality rate is very high: 15–50% of aﬀected
infants [1].
Clinical manifestations are nonspeciﬁc and laboratory
parameters such as white blood cell (WBC) count or C-
reactive protein (CRP) are of limited value in identifying in-
fected newborns. As a consequence, appropriate diagnosis
andtherapycouldbedelayed,worseningtheprognosisofthe
patient [2–6].
In studies elsewhere [4, 7, 8], the WBC count showed
a low detection sensitivity in neonatal infection. Even the
combination of total neutrophil count, immature-to-total
neutrophil ratio (I/T), and platelet count failed to reach an
appropriate sensitivity and speciﬁty in this pathology. C-
reactive protein has been thoroughly studied as a diagnostic
tool in neonatal sepsis and also as an indicator of response to
therapy [9, 10].
The underdeveloped immune system predisposes pret-
erm newborns to infection, which is a major cause of neona-
tal morbidity and mortality. Sepsis and endotoxin activate
monocytes, macrophages, lymphocytes, ﬁbroblasts, and en-
dothelial cells that produce and secrete IL-1, TNF-α, α-
interferon, IL-6, IL-8, and other proinﬂammatory cytokines.
IL-6, stimulated by TNF-α, IL-1, and endotoxin of viral and
bacterial infections, acts as a T-cell activation indicator, in-
duces antibody secretion by human B-cells, causes diﬀeren-
tiation of cytotoxic T-cells, and also has the ability to inhibit
TNF-α production. Moreover, IL-6 is the major stimulant in
hepatic protein synthesis, that is, CRP and ﬁbrinogen during
acute phase responses. Previous studies have shown that de-
terminationsofIL-6inneonatalbloodareofdiagnosticvalue
in sepsis. Elevated serum IL-1β,I L - 6 ,I L - 8 ,a n dT N F - α levels
have been found in both the neonatal and adult sepsis. Sev-
eral studies have evaluated the role of cytokine determina-
tions as early diagnostic markers in neonatal sepsis [11–17].
The aim of this study is to determine serum IL-1β,I L -
6, IL-8, and TNF-α levels in neonatal sepsis at the time of
diagnosis and after therapy and to show the meaningful on
the follow up.2 Mediators of Inﬂammation
2. MATERIAL AND METHODS
This prospective study was performed on newborns who
were hospitalized for neonatal sepsis at NICU. Inclusion
criteria were positive clinical signs of sepsis and/or history
of factors associated with increased risk for infection and
parental informed consent. Exclusion criteria were congen-
ital malformations, congenital infections associated with the
TORCH complex, and refusal of parental consent. Clinical
signs of sepsis were deﬁned as the presence of three or more
of the following categories of clinical signs: apnea, tachyp-
nea (>60/min), nasalﬂaring, retraction, cyanosis, respiratory
distress-bradycardia (<100/min), tachycardia (>180/min),
hypotonia, seizures-poor skin colour, capillary reﬁlling time
longer than two seconds, irritability, and lethargy. Histor-
ical factors associated with increased risk for infection in-
cluded premature rupture of the membranes (in term in-
fants >18 hours), maternal fever during labour, intraamni-
otic infection, and chorioamnionitis. Two or more abnor-
mal values of the sepsis screen (as white blood cell count
<4000 or >10.000mm3, immature-to-total neutrophil ra-
tio higher than 0.2 and CRP positivity) were considered as
supportive for diagnosis of infection [18]. Newborns were
classiﬁed as culture-proven sepsis (positive blood culture),
as culture-negative sepsis (negative blood culture, but clin-
ical signs of sepsis with positive sepsis screen and/or a his-
tory of risk factors, and antibiotic treatment longer than 7
days), and as control groups (healthy, noninfectious new-
borns). Blood samples were obtained at time of diagno-
sis and seventh day after antibiotic treatment, their serum
extracted and IL-1β,I L - 6 ,I L - 8 ,a n dT N F - α were deter-
mined.
Blood analysis was done in Firat Medical Center Im-
munologyLaboratory(Elazig,Turkey).Thelocalethicscom-
mission approved the study.
CRP was determined by the Behring Nephelometer 100
Analyzer BN II (NY, USA). Detection limit was 3mg/L and
as e r u mv a l u eo f>8mg/L was deﬁned as abnormally ele-
vated. The serum samples of the study and control groups
were studied by ELISA for IL-1β,I L - 6 ,I L - 8 ,a n dT N F - α
levels with human cytokine kits (Biosource, Calif, USA).
Detection limit for serum IL-1β level was 1pg/mL, mea-
sure range was 0–250pg/mL. Detection limit for serum IL-
6 level was 2pg/mL, measure range was 0–500pg/mL. De-
tection limit for serum IL-8 level was 5pg/mL, measure
range was 0–1000pg/mL. Detection limit for serum TNF-
α level was 1.7pg/mL, measure range was 0–1000pg/mL
The collected blood samples were centrifuged at 2500g
for 10 minutes at 4◦C. The serum layer was separated
a n df r o z e na t−80
◦C for cytokine analysis, which was per-
formed in less than 2 weeks. Freezing/thawing cycles were
avoided.
Statistical analyses were performed using the SPSS 11.0
programs for Windowns XP. The results were done as mean
± standard deviation. Kruskal Wallis and post hoc test
Scheﬀe procedures were used; the diﬀerence in three groups
and P<. 05 was considered to be signiﬁcant. Wilcoxon test
was used for the interpretation of the diﬀerence between at
time of diagnosis and after therapy.
3. RESULTS
In total, 50 newborns were included in the study: 12 culture-
proven sepsis, 21 culture-negative sepsis, and 17 control.
Table 1 shows the characteristics of the study group.
At time of diagnosis, serum IL-1β,I L - 6 ,I L - 8 ,a n dT N F - α
levels of culture-proven sepsis were signiﬁcantly higher than
those of the control groups (P<. 05); but only serum IL-8
levels of culture-proven sepsis was signiﬁcantly higher than
culture-negative sepsis (P<. 05).
At time of diagnosis, serum IL-1β,I L - 6 ,I L - 8 ,a n dT N F -
α levels of culture-proven sepsis and culture-negative sepsis
were signiﬁcantly higher than levels at seventh day after an-
tibiotic treatment (P<. 05).
Serum IL-1β,I L - 6 ,I L - 8 ,a n dT N F - α levels were showed
in Table 2.
4. DISCUSSION
Bacterial infection continues to be the major cause of mor-
bidity and mortality in the newborn. Because the prognosis
for sepsis largely depends on early identiﬁcation and treat-
ment, these newborns are subjected to extensive diagnos-
tic evaluation and empirical systemic antibiotic treatment,
pending laboratory results. The deﬁnitive diagnosis of sepsis
is made by a positive blood culture, which requires a mini-
mum of 48–72 hours, yields a positive result in only 30–70%
of cases, and may not always be available in peripheral health
centers. Several studies have examined the laboratory ﬁnd-
ings associated with sepsis [19–21]. There is, however, a lack
of consensus on the essential tests that would identify new-
bornswithacuteinfection.Fowlieetal.[22]c onduct edasys-
tematic review to determine the value of diagnostic tests for
bacterialinfectioninearlylife(frombirthto90daysold)and
reported that the accuracy of tests varies enormously and the
tests are of limited value in the diagnosis of infection.
Hematological parameters have been evaluated in previ-
ous studies. Da Silva et al. [23] found signiﬁcant heterogene-
ity across these studies. The possible sources of heterogeneity
were population, age, whether the subjects were at term or
preterm, methodological quality, diﬀerent leukocyte indices,
diﬀerent cutoﬀ values, and interpretation of test results by
diﬀerent laboratory observers.
In the past few decades, it has been observed that sev-
eralmediatorsofinﬂammationtendtobecomeelevateddur-
ing sepsis. The concentrations of some proinﬂammatory cy-
tokines,especiallyTNF-α, IL-6, and IL-8, in systemic circula-
tion were reported to increase in severe infections and septic
shock [24]. Martin et al. [17] showed that serum IL-6, IL-8,
and TNF-α levels were all higher in septic than in nonseptic
newborns.
ThestudyofIL-1β andTNF-α,cytokinesthataresynthe-
sized at the beginning of the inﬂammatory cascade has ren-
dered diﬀering results. In our study, the serum TNF-α and
IL-1β levels were signiﬁcantly increased in newborns with
sepsis. Results of diﬀerent published studies relation to these
cytokines are contradictory. Concerning IL-1β results, sim-
ilar to ours, they have been reported by some researchers
while not by others [25–28]. Publishing data regardingA. Nese Citak Kurt et al. 3
Table 1: Characteristics of the study groups.
Character Culture-proven sepsis
(n = 12)
Culture-negative sepsis
(n = 21) Controls (n = 17)
Gender M/F 8 / 49 / 1 38 / 9
Weight(g) 2033 ±938 2111 ±975 2294 ±761
Gestational age (weeks) 34.2 ±4.03 4 .0 ±3.33 5 .3 ±2.6
Table 2: Serum IL-1β, IL-6, IL-8, and TNF-α levels of the study groups.
Serum cytokine levels Culture-proven sepsisa
(n = 12)
Culture-negative sepsisb
(n = 21)
Controlsc (n = 17) ∗P value <. 05
IL-1β (pg/mL) At time of diagnosis1 41.20 ±13.57 33.30 ±8.62 10.35 ±2.65 a-c, b-c
7th day2 10.87 ±4.49 9.47 ±3.53
IL-6 (pg/mL) At time of diagnosis1 193.95 ±74.11 155.42 ±70.06 8.19 ±5.84 a-c, b-c
7th day2 9.45 ±6.96 8.99 ±6.08
IL-8 (pg/mL) At time of diagnosis1 481.33 ±186.58 376.85 ±96.61 55.51 ±26.54 a-b, a-c, b-c
7th day2 89.41 ±57.69 53.57 ±34.84
TNF-α (pg/mL) At time of diagnosis1 21.00 ±9.43 17.64 ±6.70 4.55 ±1.52 a-c, b-c
7th day2 5.23 ±1.74 4.92 ±1.68
∗∗P value
P<. 05 1-2 1-2 ——
∗Kruskal Wallis test.
∗∗ Wilcoxon test.
TNF-α is also divergent. Some studies found the diagnostic
utility of this cytokine [25, 26] while others demonstrated
similar or even lower levels in infected newborns compared
tohealthynewborns[29,30].Discrepanciesinresultsamong
diﬀerent studies could be explained by the variations in lab-
oratory methods in performing the analysis, the time of the
sample collection, or the control population selected [28].
Interleukin-6 has been reported as an early indicator of
neonatal sepsis because of its rapid increase after endotoxin
challenge. IL-6 is secreted by monocytes and macrophages
in response to bacteremia [31]. Previous studies have shown
IL-6 to be a useful marker of early infection in the newborn
[31–34]. Kantar et al. [31] showed that septic preterm new-
borns had signiﬁcantly elevated IL-6 levels at the onset of
sepsis as compared to the recovery period and the controls.
Inourstudy,itwasobservedthatIL-6levelsofnewbornwith
culture-provensepsisandculture-negativesepsisweresignif-
icantly higher than controls (P<. 05).
Interleukin-8 is a cytokine that has a role in the release,
activation, and chemotaxis of neutrophils. Serum IL-8 level
has been reported to increase in neonatal sepsis and have
a sensitivity of about 80–90% and a speciﬁty of about 76–
100% [35, 36]. In this study, it was detected that IL-8 lev-
els of newborns with culture-proven sepsis were signiﬁcantly
higher than culture-negative sepsis and controls (P<. 05).
Kocabasetal.[37]andMartinetal.[17]foundthatIL-8were
higher in septic than in nonseptic newborns.
Another characteristic of the markers that are used in the
diagnosis of neonatal sepsis is that it gives information about
the prognosis of the disease and helps in coming to a deci-
sion as to whether to stop or continue antibiotic treatment.
In this study, it is found that IL-1β,I L - 6 ,I L - 8 ,a n dT N F - α
levelswerestatisticallydecreasedinnewbornsafterseven-day
therapy than in newborns at the time of diagnosis (P<. 05).
Similar results have been obtained in many studies [37–39].
5. CONCLUSION
Serum levels of IL-1β,I L - 6 ,I L - 8 ,a n dT N F - α are mediators
of inﬂammation and can be used at the diagnosis and at the
evaluation of the therapeutic eﬃciency in neonatal sepsis.
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